Harvard Health Publishing
15 oktober 2020
Prof Dr K. Harvard: De tragedie van de langdurig zieke post-COVID-patiënten; Bron https://www.health.harvard.edu/blog/the ... 0101521173
How common are lingering COVID symptoms
Tens of thousands of people in the United States have such a lingering illness following COVID-19. In the US, we call them post-COVID “long haulers.” In the United Kingdom, they are said to be suffering from “long COVID.”
Published studies (see here; Bron https://jamanetwork.com/journals/jama/f ... le/2768351
and here; Bron https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392393/
) and surveys conducted by patient groups indicate that 50% to 80% of patients continue to have bothersome symptoms three months after the onset of COVID-19 — even after tests no longer detect virus in their body.Which lingering symptoms are common
The most common symptoms are fatigue, body aches, shortness of breath, difficulty concentrating, inability to exercise, headache, and difficulty sleeping. Since COVID-19 is a new disease that began with an outbreak in China in December 2019, we have no information on long-term recovery rates.
Dr. Anthony Fauci
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, has speculated that many in the second group will develop a condition called myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). ME/CFS can be triggered by other infectious illnesses — such as mononucleosis, Lyme disease, and severe acute respiratory syndrome (SARS), another coronavirus disease. The National Academy of Medicine estimates there are one million to two million people in the US with ME/CFS.
Dr. Tedros Ghebreyesus, director of the World Health Organization, also has expressed growing concern about the chronic illnesses that may follow in the wake of COVID-19, including ME/CFS.
Een interessante opmerking van Fauci dat Lyme me/cvs kan triggeren en veroorzaken.
Opmerkelijk blijft dat sommige Ilads Lyme artsen blijven zwabberen tussen de ziekten me/cvs en chronische Lyme. De me/cvs patiënten en de chronische Lyme patiënten krijgen dezelfde behandelingen en door de jaren heen geeft het bij veel patiënten onvoldoende of geen verbetering of herstel.
'Bacteriophage Lyme Test Offers ME/CFS Patient New Possibility'; Bron https://www.healthrising.org/blog/2020/ ... eriophage/
In 2020 blijken me/cvs patiënten na jaren lange behandeling met de 'Phelix Phage Borrelia test' (niet gevalideerd, in een lopend (wetenschappelijk) onderzoek) ineens Borrelia en of B. miyamotoi/Relapsing Fever te hebben?
..My wife has been ill for over seven years. She has done countless urine, feces, blood, breath, hair and saliva tests – effectively every available type of laboratory test across two continents. This included tests for Lyme and other tick-borne diseases with a specialist laboratory in the United States (ELISA, Western Blot, PCR, etc.)..
..In March, my wife tried a newly developed blood test for bacteria of the borellia genus by Phelix. The result was *positive* for Borrellia miyamotoi (one of many “cousins” of Borellia burgdorfi, the well-known bacteria that causes Lyme disease)..
..Her test results have shown some abnormalities (e.g., gut dysbiosis, abnormal metabolites, poor mitochondrial function, adrenal insufficiency, impaired T4 to T3 conversion, etc.), but never a pathogen. Like so many people with ME/CFS, she has a complex illness without a clear origin – if only she had an identifiable “bad bug” to explain it all!..
..Her doctor indicated that this pathogen could explain her very severe ME/CFS symptoms. We could hardly believe it!..
..I have learned that the new blood test is a break-through for the tick-borne illness community – and may also be a break-through for some ME/CFS patients..
In 2014 werd gezegd dat de LTT test (BCA en Arminlabs) de beste test was en meer dan 95% van de me/cvs patiënten die werden gezien geen me/cvs hadden maar de ziekte van Lyme op basis van de positieve uitslagen op Borrelia met de LTT test; Bron https://www.youtube.com/watch?v=ZGlejdfH31s
Bij de 'Phelix Phage Borrelia test' wordt over de LTT door Team Phelix Research & Development; Bron https://www.lymediseaseaction.org.uk/wp ... phages.pdf
en door Red Laboratories bij Ilads 2020 verteld vanaf 13.47 minuten; Bron https://www.youtube.com/watch?v=Mr2hKGOjCZM
Lymphocyte transformation test
- Provide indirect evidence
- Variable sensitivity
- Can only detect Lymphocytes that have been in contact with Borrelia within 45±15 days, thus limited in application
- Distinguish active Borrelia?
- Distinguish different Borrelia sub-types?
Bron viewtopic.php?f=38&t=2435#p25490 Over de LTT test
Louis Teulieres: 'Of course, as the LTT depends on the status of the immune system: the response can be impaired by intercurrent antibiotics immune modulators essential oils. It can also be exaggerated by the time length of antigens' exposure. (Be cautious with some labs
) The lymphocytes' memory can fade ad vanish after some time
. Alto nether LTT is a rather fragile test (risk of false negative and many false positive above all in small scores
) If lTT is really and highly positive; its reliable. Otherwise ... PCR Phage test is not questionable if positive Sensitivity is higher than normal PCR and LTT. It is the proof of the existence of living bacteria. For the time being PCR Phage test is also the only robust test for miyamotoï'
'The lymphocytes' memory can fade ad vanish after some time'.. Is dat juist? Het zou goed zijn als het gestelde door de onderzoekers en Red Laboratories wetenschappelijk onderbouwd kan worden en er over gepubliceerd gaat worden.
Met welke Covid-19 test heeft Louis Teulières en of Red Laboratories gewerkt bij de 2.100 - 2.200 samples (all late stage) van de patiënten?; Bron https://www.ilads.org/ilads-conference/ ... ecific-pcr
..Interestingly, 20 positive patients were also early stage symptomatic COVID -19 cases..
..Tick biting season should provide genetic typing in early stages, (before antibody production) that will be presented. Early sequential treatment may be helpful to limit serious cases of COVID-19 incidence and tackle morbidities due to LD/COVID coinfections..